This most up-to-date twist within the Lykos Therapeutics saga threatens a major overhaul of the company’s strategy and direction, with Musk ally and billionaire Trader Antonio Gracias showing to need to just take the company again towards its nonprofit drug growth roots and a more Doblinite philosophy.On the list of vital features with the Portal